Collected Works of Kanti R. Rai

Introduction

Dr. Kanti Rai is the founder of the Rai Clinical Staging System for CLL, published in 1975. In 2000, he produced the definitive comparative study of chlorambucil and fludarabine in the treatment of the CLL patient. Subsequently, he studied the combined use of fludarabine and cytoxan, the combined use fludarabine and rituximab, and the combination of all three. He has also been at the forefront of defining many of the molecular prognostic markers that have emerged in the last few years and of defining the molecular lesions involving mir15/mir16a associated with the 13q14 deletion in CLL.

Dr. Rai was Born in Jodhpur, India, and is a graduate of Sawai ManSingh (SMS) Medical College, University of Rajasthan, in Jaipur. He began his early medical training in pediatric medicine at Lincoln Hospital and North Shore University Hospital in New York. He completed a fellowship in hematology and nuclear medicine at Long Island Jewish (LIJ) Medical Center. He went on to join the Hematopoetic Cell Kinetics research team at the Brookhaven National Laboratory (BHL). Dr. Rai has been a member of ASCO since 1970. He is a member of the board of directors for the CLL Research Consortium (CRC), a founding member of iwCLL, and member of the Cancer and Leukemia Group B (CALGB). In 2006, he served as the president of the American Society of Hematology.

A set of video clips in which Dr. Rai discusses the development of his research may be found in the Oral history archive.

Collected Works

1960

• Jansen CR, Baker C, Calvo, W. Rai KR, Lippincot SW. A Method Of Effectively Widening The Bragg Peak In Depth In The Path Of Charged Heavy Particles In Tissue. Upton, NY: Brookhaven National Lab; 1960. Report No. BNL-5538. 

1962

• Greenberg J, Sawitsky A, Dudley HC, Levy RN, Rai KR. Therapy of polycythemia vera with radiotytrium (Y-90). J Nucl Med. 1962 Jan;3:18-25.
• Greenberg J, Sawitsky A, Weisfuse L, Levy RN, Rai KR, Dudley HC. Therapy of multiple myeloma with radiotytrium (Y90). J Lab Clin Med. 1962 Jun;59:898-904.
• Hankes LV, Schmaeler M, Rai K. O-Aminophenol: a urinary product of tryptophan metabolism in the human. Proc Soc Exp Biol Med. 1962 Jul;110:420-2.
• Jansen CR, Cronkite EP, Mather GC, Nielsen NO, Rai K, Adamik ER, Sipe CR. Studies on lymphocytes. II. The production of lymphocytosis by intravenous heparin in calves. Blood. 1962 Oct;20:443-52. 

1963

• Cronkite EP, Jansen CR, Rai KR, Cottier H, Fliedner TM, The combined application of lymph duct drainage and extracorporeal irradiation of the blood in the study of lymphopoiesis. In Fry RJM, Lamerton LF, Eds. Cell Proliferation: A Guiness Symposium. Oxford, England: Blackwell Scientific Publications; 1963:126-156.
• Lippincott SW, Jesseph JE, Baker CP, Calvo WG, Jansen CR, Rai KR, Alcober V. Effects of heavy high energy charged particles. II. Primary atypical epithelial hyperplasia in mouse skin after exposure to 10 mev protons, 20 mev deuterons, or 40 mev alpha-particles. Arch Pathol. 1963 Nov;76:527-36.

1964

• Cronkite EP, Jansen CR, Cottier H, Rai KR, Sipe CR. Lymphocyte production measured by extracorporeal irradiation, cannulation, and labeling techniques. Ann N Y Acad Sci. 1964 Feb 28;113:566-77. 
• Lippincott SW, Corcoran C, Jansen CR, Jesseph JE, Rai KR, Aranow S, Green MW, Sweet WH. Labeling of human globulin with I-124 for positron scanning of neoplasms. J Nucl Med. 1964 Mar;5:193-9. 
• Jansen CR, Bond VP, Rai KR, Lippincott SW. Abscopal effects of localized irradiation by accelerator beams. Ann N Y Acad Sci. 1964 Mar 31;114:302-15. 
• Cottier H, Cronkite EP, Jansen CR, Rai KR, Singer S, Sipe CR. Studies on lymphocytes. III. Effects of extracorporeal irradiation of the circulating blood upon the lymphoreticular organs in the calf. Blood. 1964 Sep;24:241-53. 

1967

• Safier S, Wagner HP, Cottier H, Rai KR, Jansen CR, Cronkite EP. Lymphoid cell lines in the thoracic duct of the calf with different generation times. In Cottier H, Odartchenko N, Schindler R, Congdon CC, Eds. Germinal Centers in Immune Responses. Berlin, Germany: Springer-Verlag Berlin Heidelberg; 1967:161-167. 
• Wagner HP, Cottier H, Cronkite EP, Cunningham L, Jansen CR, Rai KR. Studies on lymphocytes. V. Short in vivo DNA synthesis and generation time of lymphoid cells in the calf thoracic duct after simulated or effective extracorporeal irradiation of circulating blood. Exp Cell Res. 1967 May;46(2):441-51. 
• Cunningham L, Cottier H, Cronkite EP, Jansen CR, Rai KR, Safier S, Wagner HP. Studies on lymphocytes. VIII. Short in vivo mitotic time of basophilic lymphoid cells in the thoracic duct of calves after simulated or effective extracorporeal irradiation of circulating blood. Exp Cell Res. 1967 Sep;47(3):479-88. 
• Safier S, Cottier H, Cronkite EP, Jansen CR, Rai KR, Wagner HP. Studies on lymphocytes. VI. Evidence showing different generation times for cytologically different lymphoid cell lines in the thoracic duct of the calf. Blood. 1967 Sep;30(3):301-10. 

1968

• Cronkite EP, Rai KR, Chanana AD, Joel DD, Schiffer LM. Influence of extracorporeal irradiation of the blood and lymph and lymphopoiesis and immunity. In Effects of radiation on cellular proliferation and differentiation. Proceedings of a symposium on the effects of radiation on cellular proliferation and differentiation organized by the International Atomic Energy Agency in co-operation with the Joint Commission on Applied Radioactivity and held in Monaco, 1-5 April 1968.
• Chanana AD, Cronkite EP, Greenberg ML, Rai KR, Schiffer LM, Stryckmans PA, Vincent PC. Experience with arteriovenous shunts in leukemic patients. Arch Surg. 1968 Jul;97(1):154-60. 
• Schiffer LM, Chanana AD, Cronkite EP, Greenberg ML, Rai K, Stryckmans P, Vincent P. L’irradiation extra-corporelle du sang dans la leucémie lymphoïde chronique. Nouv Rev Fr Hematol. 1968 Sep-Oct;8(5):691-700.

1969

• Rai KR, Chanana AD, Cronkite EP, Joe DD, Schiffer LM. Studies On Lymphocytes. XV. The Influence Of Transit Dose Upon Lymphocytopenia Induced By Extracorporeal Irradiation Of Blood (ECIB) In Calves. Upton, NY: Brookhaven National Lab; 1969. Report No. 13077.
• Schiffer LM, Chanana AD, Cronkite EP, Greenberg ML, Okuyama S, Rai KR, Robertson VS, Stryckmans PA, Vincent PC. Lymphocyte kinetics in chronic lymphocytic leukaemia (CLL) studied by ECIB. Br J Haematol. 1969 Oct;17(4):408. 

1970

• Schaer H, Schindler R, Roos B, Cottier H, Rai KR, Cronkite EP. Umsatz von lymphozyten in blut und lymphknoten der ratte. Autoradiographische untersuchungen mit hilfe langzeitig weiderholter injektionen von thymidin-3H. Z Zellforsch Mikrosk Anat. 1970;111(1):75-89.
• Okuyama S, Aronson RB, Chanana AD, Cronkite EP, Rai KR, Schiffer LM. Attempts at isolation of lymphocytosis-producing factor from supernatant fluids of Bordetella pertussis cultures. Proc Soc Exp Biol Med. 1970 Feb;133(2):723-7.
• Ruchti C, Cottier H, Cronkite EP, Jansen CR, Rai KR. Studies on lymphocytes. XVII. Differential lymphocyte depletion in lymphoreticular organs of the calf during continuous extracorporeal x-irradiation of the circulating blood. Cell Tissue Kinet. 1970 Jul;3(3):301-15.
• Rai KR, Basu AK, Khanduja PC, Agarwal KN. Determination of the functional extracellular fluid volume (ECFV) by sodium-24 chloride. Indian J Med Res. 1970 Aug;58(8):1038-43.

1971

• Rai KR, Chanana AD, Cronkite EP, Gulliani GL, Joel DD. Studies on the leukocytopenia due to acute effects of supernatant fluids of Bordetella pertussis cultures. Proc Soc Exp Biol Med. 1971 Feb;136(2):433-8.
• Rai KR, Chanana AD, Cronkite EP, Joel DD, Stevens JB. Studies on lymphocytes XVIII. Mechanism of lymphocytosis induced by supernatant fluids of Bordetella pertussis cultures. Blood. 1971 Jul;38(1):49-59. 

1972

• Cheung WH, Rai KR, Sawitsky A. Characteristics of cell proliferation in acute leukemia. Cancer Res. 1972 May;32(5):939-42.

1974

• Fu SM, Winchester RJ, Rai KR, Kunkel HG. Hairy cell leukemia: proliferation of a cell with phagocytic and B-lymphocyte properties. Scand J Immunol. 1974;3(6):847-51. 

1975

• Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219-34. 
• Gulliani GL, Chanana AD, Cronkite EP, Joel DD, Laissue J, Rai KR. Survival of chromium-51-labeled autologous and homologous erythrocytes in goats. Am J Vet Res. 1975 Oct;36(10):1469-71.

1976

• Chanana AD, Cronkite EP, Rai KR. The role of extracorporeal irradiation of blood in treatment of leukemia. Int J Radiat Oncol Biol Phys. 1976 Mar-Apr;1(5-6):539-48. 
• Holland JF, Glidewell O, Ellison RR, Corey RW, Schwartz J, Wallace HJ, Hoagland HC, Wiernik P, Rai K, Bekesi JG, Cuttner J. Acute myelocytic leukemia. Arch Intern Med. 1976 Dec;136(12):1377-81. 
• Sawitsky A, Rai KR, Aral I, Silver RT, Glicksman AS, Carey RW, Scialla S, Cornell CJ Jr, Seligman B, Shapiro L. Mediastinal irradiation for chronic lymphocytic leukemia. Am J Med. 1976 Dec;61(6):892-6. 

1977

• Sawitsky A, Rai KR, Glidewell O, Silver RT. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood. 1977 Dec;50(6):1049-59. 

1978

• Sawitsky A, Rai KR. The chronic leukemias. In Conn HF, Ed. Current Therapy. Philadelphia, PA: W. B. Saunders; 1978:315-321.
• Silver RT, Sawitsky A, Rai K, Holland JF, Glidewell O. Guidelines for protocol studies in chronic lymphocytic leukemia. Am J Hematol. 1978;4(4):343-58. 

1979

• Chiorazzi N, Fu SM, Montazeri G, Kunkel HG, Rai K, Gee T. T cell helper defect in patients with chronic lymphocytic leukemia. J Immunol. 1979 Mar;122(3):1087-90. https://www.jimmunol.org/content/122/3/1087.long
• Kanter RJ, Freiberger IA, Rai KR, Sawitsky A. Lymphocyte populations with 5′-nucleotidase in chronic lymphocytic leukemia. Clin Immunol Immunopathol. 1979 Mar;12(3):351-7. https://doi.org/10.1016/0090-1229(79)90039-4
• Chandra P, Sawitsky A, Chanana AD, Chikkappa G, Cohn SH, Rai KR, Cronkite EP. Correlation of total body potassium and leukemic cell mass in patients with chronic lymphocytic leukemia. Blood. 1979 Apr;53(4):594-603. https://doi.org/10.1182/blood.V53.4.594.594
• Kerpen HO, Bhat JG, Kantor R, Gauthier B, Rai KR, Schacht RG, Baldwin DS. Lymphocyte subpopulations in minimal change nephrotic syndrome. Clin Immunol Immunopathol. 1979 Sep;14(1):130-6. https://doi.org/10.1016/0090-1229(79)90133-8

1980

• Coleman M, Silver RT, Pajak TF, Cavalli F, Rai KR, Kostinas JE, Glidewell O, Holland JF. Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. Blood. 1980 Jan;55(1):29-36. 
• Lipshutz MD, Mir R, Rai KR, Sawitsky A. Bone marrow biopsy and clinical staging in chronic lymphocytic leukemia. Cancer. 1980 Sep 15;46(6):1422-7.

1981

• Rai KR, Sawitsky A. Chronic myelocytic leukemia. In Crooke ST, Prestayko AW, Eds. Cancer and Chemotherapy. Volume 2. New York, NY: Academic Press; 1981:57-68.
• Rai KR, Sawitsky A. Studies in clinical staging, lymphocyte function, and markers as an approach to the treatment of chronic lymphocytic function. In Silber R, Gordon AS, Lobue J, Muggia FO, Eds. Contemporary Hematology/Oncology. Volume 2. New York, NY: Plenum; 1981:227-262.
• Sawitsky A, Rai KR. Chronic lymphocytic leukemia.In Newsom SR, Ed. Hematologic Malignancies in the Adult. Menlo Park, CA: Addison-Wesley; 1981:179-192.
• Binet JL, Catovsky D, Chandra P, Dighiero G, Montserrat E, Rai KR, Sawitsky A. Chronic lymphocytic leukaemia: proposals for a revised prognostic staging system. Report from the International Workshop on CLL. Br J Haematol. 1981 Jul;48(3):365-7. 
• Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchison JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981 Dec;58(6):1203-12. 

1982

• Sawitsky A, Rai KR. Chronic lymphocytic leukemia. In Greenspan EM, Ed. Clinical Interpretation and Practice of Cancer Chemotherapy. New York, NY: Raven Press; 1982:577-597.
• Cohn SH, Vartsky D, Vaswani AN, Sawitsky A, Rai K, Gartenhaus W, Yasumura S, Ellis KJ. Changes in body composition of cancer patients following combined nutritional support. Nutr Cancer. 1982;4(2):107-19. 
• Kanter RJ, Rai KR, Muniz F, Michael B, Balkon J, Sawitsky A. Intracellular zinc in chronic lymphocytic leukemia. Clin Immunol Immunopathol. 1982 Jul;24(1):26-32. 

1984

• Rai KR, Sawitsky A. Treatment of chronic lymphocytic leukemia. In Wiernik P, Canellos G, Kyle R, Schiffer C, Eds. Contemporary Issues in Clinical Oncology. New York, NY: Churchill Livingston; 1984:213-225.
• Preisler HD, Epstein J, Raza A, Azarnia N, Browman G, Booker L, Goldberg J, Gottlieb A, Brennan J, Grunwald H, Rai K, Vogel R, Winton L, Miller K, Larson R. Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease. Eur J Cancer Clin Oncol. 1984 Aug;20(8):1061-8. 

1985

• Rai KR, Cronkite EP, Sawitsky A, Chandra P, Steinberg J. Studies in chronic lymphocytic leukemia: blood lymphocyte surface characteristics and immunologic functional status of patients and correlation with clinical stage. Ann N Y Acad Sci. 1985;459:336-43. 
• Preisler HD, Raza A, Azarnia N, Rakowsky I, Barcos M, Browman G, Booker L, Goldberg J, Gottleib A, Brennan J, Grunwald H, Rai K, Miller K, Vogler R, Winton L, Larson R. Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: relationship to response to remission induction therapy. Eur J Cancer Clin Oncol. 1985 May;21(5):563-71. 
• Goldberg J, Grunwald H, Vogler WR, Winton E, Browman G, Walker I, Benger A, Miller KB, Rai K, Gottlieb AJ, Brennan JK, Bennet JM, Chervenic P, Joyce R, Azarnia N, Priore RL, Preisler HD. Treatment of patients with acute nonlymphocytic leukemia in relapse: a Leukemia Intergroup study. Am J Hematol. 1985 Jun;19(2):167-76. 

1986

• Rai KR, Sawitsky A. Chronic lymphocytic leukemia. In Moossa AR, Robson MC, Schimpff SC, Eds. Comprehensive Textbook on Oncology. Baltimore, MD: Williams & Wilkins; 1986:547-551.
• Vogler WR, Preisler HD, Winton EF, Gottlieb AJ, Goldberg J, Brennan J, Grunwald H, Rai K, Browman G, Miller KB, Chervenick P, Azarnia N. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study. Cancer Treat Rep. 1986 Apr;70(4):455-9.
• Preisler HD, Priore R, Azarnia N, Barcos M, Raza A, Rakowski I, Vogler R, Winton EL, Browman G, Goldberg J, Gottlieb AJ, Grunwald H, Rai K, Miller K, Brennan J, Chervenick P, Joyce R, Tricot G. Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements. Br J Haematol. 1986 Aug;63(4):625-36. 

1987

• Gale RP, Rai KR. Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. New York, NY: Alan R. Liss; 1987.
• Rai KR. A critical analysis of staging in CLL. In Gale RP, Rai KR, Eds. Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. New York, NY: Alan R. Liss; 1987:253-264.
• Rai KR, Gale RP. Chronic lymphocytic leukemia: future directions. In Gale RP, Rai KR, Eds. Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. New York, NY: Alan R. Liss; 1987:419-423.
• Sawitsky A, Rai KR. The chronic lymphoid leukemias. In Whittaker JA, Delamore IW, Eds. Leukemia. Oxford, England: Blackwell Scientific Publications; 1987:383-406.
• Rai KR, Cuttner J, Holland JF, Davis R, Mayer R, McIntyre OR, Preisler H, Yates J. Therapeutic strategies in acute myelocytic leukemia: a status report of the experience of CALGB. Cancer and Leukemia Group B. Haematol Blood Transfus. 1987;30:31-4. 
• Rai KR, Rosner F. The chronic leukemias. Curr Hematol Oncol. 1987;5:149-169.
• Rai KR, Sawitsky A. A review of the prognostic role of cytogenetic, phenotypic, morphologic, and immune function characteristics in chronic lymphocytic leukemia. Blood Cells. 1987;12(2):327-38.
• Mayer RJ, Schiffer CA, Peterson BA, Budman DR, Silver RT, Rai KR, Cornwell GG, Ellison RR, Maguire M, Berg DT, Davis RB, McIntyre OR, Frei E III. Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B. Semin Oncol. 1987 Jun;14(2 Suppl 1):25-31.
• Rai KR, Montserrat E. Prognostic factors in chronic lymphocytic leukemia. Semin Hematol. 1987 Oct;24(4):252-6.

1988

• Rai KR. Chronic lymphocytic leukemia. In Brain MC, Carbone PP, Eds. Current Therapy In Hematology-Oncology. Philadelphia, PA: B. C. Decker; 1988:58-60.
• Rai KR. Treatment of chronic lymphocytic leukemia. In Huang AT, Ed. Hairy Cell and Chronic Lymphocytic Leukemia: Thirty Years of Progress. New York, NY: Elsevier; 1988:190-193.
• Rai KR, Sawitsky A. The different staging systems proposed in chronic lymphocytic leukemia. In Polliack A, Catovsky D, Eds. Chronic Lymphocytic Leukemia. Chur, Switzerland: Harwood Academic; 1988:105-110.
• Shustik C, Mick R, Silver R, Sawitsky A, Rai K, Shapiro L. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol. 1988 Jan-Mar;6(1):7-12. 
• Lieberman JA, Johns CA, Kane JM, Rai K, Pisciotta AV, Saltz BL, Howard A. Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry. 1988 Jul;49(7):271-7.

1989

• Gale RP, Binet JL, Catovsky D, Dighiero G, Montserrat E, Rai KR, Rozman C, Sawitsky A. 4th International Workshop on CLL. Leuk Res. 1989;13(6):505-510. 
• Binet JL, Catovsky D, Dighiero G, Gale RP, Montserrat E, Rai KR, Rozman C, Sawitsky A. Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. Ann Intern Med. 1989 Feb 1; 110 (3): 236-238. 
• Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Oken MM, Schiffer CA, Keating MJ, Boldt DH, Kempin SJ, Foon KA. Chronic lymphocytic leukemia: recommendations. Ann Intern Med. 1989 Apr 15;110(8):664-5. 

1990

• Han T. Rai KR. Chronic lymphocytic leukemia. In Henderson ES, Lister TA, Eds. Leukemia. Fifth Edition. New York, NY: W. B. Saunders; 1990:565-611.
• Rai KR. Chronic lymphocytic leukemia. In Hoffman R, Benz EJ, Shattil SJ, et al., Eds. Hematology: Basic Principles and Practice. New York, NY: Churchill Livingstone; 1990: 990-1001.
• Han T, Rai KR. Management of chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 1990 Apr;4(2):431-45. 
• Rai KR, Han T. Prognostic factors and clinical staging in chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 1990 Apr;4(2):447-56. 
• Wormsley SB, Baird SM, Gadol N, Rai KR, Sobol RE. Characteristics of CD11c+CD5+ chronic B-cell leukemias and the identification of novel peripheral blood B-cell subsets with chronic lymphoid leukemia immunophenotypes. Blood. 1990 Jul 1;76(1):123-30. 
• Santiago-Schwarz F, Panagiotopoulos C, Sawitsky A, Rai KR. Distinct characteristics of lymphokine-activated killer (LAK) cells derived from patients with B-cell chronic lymphocytic leukemia (B-CLL). A factor in B-CLL serum promotes natural killer cell-like LAK cell growth. Blood. 1990 Oct 1;76(7):1355-60. 

1991

• Rai KR. Chronic lymphocytic leukemia. In Kassierer JP, Ed. Current Therapy in Internal Medicine. Philadelphia, PA: M. C. Decker; 1991:838-841.
• Rai KR, Sawitsky A. Chronic lymphocytic leukemia. In Moosa AR, Schimpff SC, Robson MC, Eds. Comprehensive Textbook of Oncology. Philadelphia, PA: William & Wilkins; 1991:1220-1224.
• Rai KR, Sawitsky A. Diagnosis and treatment of chronic lymphocytic leukemia. In Wiernik P, Canellos GP, Kyle RA, Schiffer C, Eds. Neoplastic Diseases Of The Blood. New York, NY: Churchill Livingston; 1991:97-109.
• Ball ED, Davis RB, Griffin JD, Mayer RJ, Davey FR, Arthur DC, Wurster-Hill D, Noll W, Elghetany MT, Allen SL, Rai K, Lee EJ, Schiffer CA, Bloomfield CD. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood. 1991 May 15;77(10):2242-50. 

1992

• Rai KR. Chronic lymphocytic leukemia. In Brain MC, Carbone PP, Eds. Current Therapy In Hematology/Oncology. Philadelphia, PA: B. C. Decker; 1992:51-54.
• Sawitsky A, Rai KR. The chronic lymphoid leukaemias. In Whittaker JA, Ed. Leukaemia. Boston, MA: Blackwell Scientific Publications; 1992:468-494.
• Montserrat E, Binet JL, Catovsky D, Dighiero G, Gale RP, Rai KR, Rozman C. 5th International Workshop on Chronic Lymphocytic Leukemia. Leuk Res. 1992 Jun-Jul;16(6-7):717-20. 

1993

• Foon KA, Rai KR, Gale RP. Chronic lymphocytic leukemia. In Bick RL, Ed. Hematology: clinical and laboratory practice. St. Louis, MO: Mosby; 1993:803-814.
• Rai KR. An outline of clinical management of chronic lymphocytic leukemia. In Cheson B, Ed. Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments. New York, NY: Marcel Dekker; 1993:241-251.
• Rai KR, Rabinowe SN. Chronic lymphocytic leukemia. In Holland JF, Frei E III, Bast RC Jr, et al., Eds. Cancer Medicine. Third Edition. Philadelphia, PA: Lea & Febiger; 1993:1971-1988.
• Rai KR. Progress in chronic lymphocytic leukaemia: a historical perspective. Baillieres Clin Haematol. 1993 Dec;6(4):757-65.

1994

• Rai KR. Comparison of pentostatin and alpha interferon in splenectomized patients with active hairy cell leukemia: an intergroup study. Cancer and Leukemia Group B and South-West Oncology Group. Leuk Lymphoma. 1994;14(Suppl 1):107-8.
• Hoffman M, Tallman MS, Hakimian D, Janson D, Hogan D, Variakogis D, Kuzel T, Gordon LI, Rai K. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin’s lymphoma. J Clin Oncol. 1994 Apr;12(4):788-92. https://doi.org/10.1200/JCO.1994.12.4.788
• Montserrat E, Binet JL, Dighiero G, Gale RP, Juliusson G, Keating M, Rai KR. Chronic lymphoproliferative disorders. Rev Invest Clin. 1994 Apr;Suppl:52-8.
• Ney GC, Schaul N, Loughlin J, Rai K, Chandra V. Thrombocytopenia in association with adjunctive felbamate use. Neurology. 1994 May;44(5):980-1. 
• Gale RP, Caligaris-Cappio F, Dighiero G, Keating M, Montserrat E, Rai K. Recent progress in chronic lymphocytic leukemia. International Workshop on chronic Lymphocytic Leukemia. Leukemia. 1994 Sep;8(9):1610-4.
• Siegal FP, Shodell M, Shah K, Drake D, Hoffman M, Sawitsky A, Janson D, Fitzgerald-Bocarsly P, Rai KR. Impaired interferon alpha response in hairy cell leukemia is corrected by therapy with 2-chloro-2′-deoxyadenosine: implications for susceptibility to opportunistic infections. Leukemia. 1994 Sep;8(9):1474-9.

1995

• Rai KR, Billett H. Hematologic Disorders. In Seltzer VL, Pearse WH, Eds. Women’s Primary Health Care: Office Practice and Procedures. New York, NY: McGraw Hill; 1995:585-599.
• Rai KR, Patel D. Chronic lymphocytic leukemia. In Hoffman R, Benz EJ, Shattil SJ, et al., Eds. Hematology: Basic Principles and Practice. 2nd edition. New York, NY: Churchill Livingston; 1995:1308-1321.
• Hoffman MA, Valderrama E, Fuchs A, Friedman M, Rai K. Leukemic meningitis in B-cell prolymphocytic leukemia. A clinical, pathologic, and ultrastructural case study and a review of the literature. Cancer. 1995 Mar 1;75(5):1100-3.
• Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth PA, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995 Apr;13(4):974-82. 
• Rai KR, Davey F, Peterson B, Schiffer C, Silver RT, Ozer H, Golomb H, Bloomfield CD. Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia. 1995 Jul;9(7):1116-20.

1996

• Gartenhaus R, Johns MM, Wang P, Rai K, Sidransky D. Mutator phenotype in a subset of chronic lymphocytic leukemia. Blood. 1996 Jan 1;87(1):38-41. 
• Gartenhaus RB, Wang P, Hoffman M, Janson D, Rai KR. The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine. J Mol Med (Berl). 1996 Mar;74(3):143-7. 
• Soni M, Brody J, Allen SL, Schulman P, Kolitz J, Rai K, Broome JD, Koduru PR. Clinical and morphological features of cases of trisomy 13 in acute non-lymphocytic leukemia. Leukemia. 1996 Apr;10(4):619-23.
• Gartenhaus R, Hoffman M, Fuchs A, Billet H, Wang P, Gentile P, Rai K. Differentiating agents do not induce a true hairy cell phenotype in B-CLL cells in vitro. Leuk Lymphoma. 1996 Jun;22(1-2):97-101, follow.186, color plate IX. 
• Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O’Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996 Jun 15;87(12):4990-7. 
• Alter CL, Fleishman SB, Kornblith AB, Holland JC, Biano D, Levenson R, Vinciguerra V, Rai KR. Supportive telephone intervention for patients receiving chemotherapy. A pilot study. Psychosomatics. 1996 Sep-Oct;37(5):425-31. 
• Fais F, Sellars B, Ghiotto F, Yan X-J, Dono M, Allen SL, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Schuster M, Vinciguerra VP, Rai K, Stevenson F, Gregersen PK, Ferrarini M, Chiorazzi N. Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells. J Clin Invest. 1996 Oct 1;98(7):1659-66. 

1997

• Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol. 1997 Mar;15(3):1138-42. 
• Rai KR. Chronic lymphocytic leukemia in the elderly population. Clin Geriatr Med. 1997 May;13(2):245-9. 

1998

• Byrd JC, Rai KR, Sausville EA, Grever MR. Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol. 1998 Feb;25(1):65-74.
• Rai KR. Cladribine for the treatment of hairy cell leukemia and chronic lymphocytic leukemia. Semin Oncol. 1998 Jun;25(3 Suppl 7):19-22.
• Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission. Leuk Res. 1998 Nov;22(11):973-81. 

1999

• Rai KR. Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment. Haematologica. 1999 Jun;84 Suppl EHA-4:94-5.
• Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. Leuk Res. 1999 Aug;23(8):709-18. 
• Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase. Leuk Res. 1999 Sep;23(9):817-26. 
• Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999 Sep 15;94(6):1840-7. 
• Rai KR. Future strategies toward the cure of indolent B-cell malignancies. New biologic therapies. Semin Hematol. 1999 Oct;36(4 Suppl 5):12-7.

2000

• Fais F, Ghiotto F, Hashimoto S, Dono M,Valetto A, Allen SL, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. Immunoglobulin V gene sequence analyses distinguish two subsets of chronic lymphocytic leukemia B cells. In Zanetti M, Capra JD, eds. The Antibodies. Vol 6. Amsterdam, Netherlands: Harwood Academic; 2000:123-150.
• Damle RN, Fais F, Ghiotto F, Valetto A, Albesiano E, Wasil T, Batliwalla FM, Allen SL, Schulman P, Vinciguerra VP, Rai KR, Gregersen PK, Ferrarini M, Chiorazzi N. Chronic lymphocytic leukemia: A proliferation of B cells at two distinct stages of differentiation. Curr Top Microbiol Immunol. 2000;252:285-92.
• Byrd JC, Rai KR. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory? Semin Oncol. 2000 Aug;27(4):xii-xv; discussion xv-xvi.
• Byrd JC, Waselenko JK, Rai KR, Keating MJ, Grever MR. Novel therapies for chronic lymphocytic leukemia in the 21st century. Semin Oncol. 2000 Oct;27(5):587-97.
• Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, Corbett W, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever MR. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000 Nov 1;96(9):2981-6. 
• Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 14;343(24):1750-7. 

2001

• Byrd JC, Rai KR. Chemotherapy and immunotherapy in chronic lymphocytic leukemia and hairy cell leukemia. In Perry M, ed. The Chemotherapy Source Book. Third edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:839-849.
• Poiesz BJ, Papsidero LD, Ehrlich G, Sherman M, Dube S, Poiesz M, Dillon K, Ruscetti FW, Slamon D, Fang C, Williams A, Duggan D, Glaser J, Gottlieb A, Goldberg J, Ratner L, Phillips P, Han T, Friedman-Kien A, Siegal F, Rai K, Sawitsky A, Sheremata LW, Dosik H, Cunningham C, Montagna R. Prevalence of HTLV-I-associated T-cell lymphoma. Am J Hematol. 2001 Jan;66(1):32-8. 
• Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Martell RE, Larson RA, Schiffer CA. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 2001 Aug 15;19(16):3611-21. 

2002

• Ahmed S, Siddiqui AK, Rai KR. Low-grade B-cell bronchial associated lymphoid tissue (BALT) lymphoma. Cancer Invest. 2002;20(7-8):1059-68. 
• Ludwig H, Rai K, Blade J, Dammacco F, Degos L, Itri L, Kyle R, Liso V, Littlewood TJ, Mandelli F, Meloni G, Molica S, Osterborg A, Pangalis GA, San Miguel J, Schmitt B, Voliotis D. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J. 2002;3(3):121-30.
• Rai RK. Campath-1H for chronic lymphocytic leukemia. Clin Lymphoma. 2002;3(2):73-4. 
• Rai K, Hallek M. Future prospects for alemtuzumab (MabCampath). Med Oncol. 2002;19 Suppl:S57-63. 
• Keating MJ, Cazin B, Coutré S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjønnfjord G, Bekradda M, Itzhaki M, Hérait P. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002 Jan 1;20(1):205-13. 
• Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002 May 15;99(10):3554-61. 
• Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan X-J, Sison CP, Allen SL, Kolitz J,Schulman P, Vinciguerra VP, Budde P, Frey J, Rai KR, Ferrarini M, Chiorazzi N. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 2002 Jun 1;99(11):4087-93. 
• Martell RE, Peterson BL, Cohen HJ, Petros WP, Rai KR, Morrison VA, Elias L, Shepherd L, Hines J, Larson RA, Schiffer CA, Hurwitz HI. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol. 2002 Jul;50(1):37-45. Epub 2002 Apr 27. 
• Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santábarbara P, Wacker B, Brettman L. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002 Sep 15;20(18):3891-7. 
• Gupta N, Kavuru S, Patel D, Janson D, Driscoll N, Ahmed S, Rai KR. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 2002 Oct;16(10):2092-5. https://doi.org/10.1038/sj.leu.2402676
• Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9. Epub 2002 Nov 14. 
• Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, Kipps TJ. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002 Dec 15;100(13):4609-14. Epub 2002 Aug 8. 

2003

• Keating MJ, Chiorazzi N, Messmer BT, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps TJ. Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003:153-75. 
• Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JR, Rai K, Schiffer CA, Larson RA. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003 Jan 1;101(1):6-14. Epub 2002 Jul 5. 
• Ahmed S, Rai KR. Interferon in the treatment of hairy-cell leukemia. Best Pract Res Clin Haematol. 2003 Mar;16(1):69-81. 
• Rai KR, Chiorazzi N. Determining the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med. 2003 May 1;348(18):1797-9. 
• Ahmed S, Siddiqui AK, Rossoff L, Sison CP, Rai KR. Pulmonary complications in chronic lymphocytic leukemia. Cancer. 2003 Nov 1;98(9):1912-7. 
• Albesiano E, Messmer BT, Damle RN, Allen SL, Rai KR, Chiorazzi N. Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. Blood. 2003 Nov 1;102(9):3333-9. Epub 2003 Jul 10. 

2004

• Rai KR, Gupta N. Staging of chronic lymphocytic leukemia. In Faguet GB, ed. Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management. Totowa, NJ: Humana Press Inc. 2004; 193-199.
• Schiemann WP, Rotzer D, Pfeifer WM, Levi E, Rai KR, Knaus P, Kadin ME. Transforming growth factor-β (TGF-β)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-beta receptor. Cancer Detect Prev. 2004;28(1):57-64. 
• Wasil T, Rai KR, Mehrotra B. The role of monoclonal antibodies in stem cell transplantation. Semin Oncol. 2004 Feb;31(1):83-9. 
• Ghiotto F, Fais F, Valetto A, Albesiano E, Hashimoto S, Dono M, Ikematsu H, Allen SL, Kolitz J, Rai KR, Nardini M, Tramontano A, Ferrarini M, Chiorazzi N. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest. 2004 Apr;113(7):1008-16. 
• Ahmed S, Kussick SJ, Siddiqui AK, Bhuiya TA, Khan A, Sarewitz S, Steinberg H, Sison CP, Rai KR. Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease. Eur J Cancer. 2004 Jun;40(9):1320-6. 
• Rai KR. Exciting new developments in chronic lymphocytic leukemia: an introduction and an editorial. Semin Hematol. 2004 Jul;41(3):189-90. 
• Messmer D, Telusma G, Wasil T, Messmer BT, Allen SL, Rai KR, Chiorazzi N. Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status. Mol Med. 2004 Jul-Dec;10(7-12):96-103. 
• Rai KR, Wasil T, Iqbal U, Driscoll N, Patel D, Janson D, Mehrotra B. Clinical staging and prognostic markers in chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 2004 Aug;18(4):795-805, vii. 
• Messmer BT, AlbesianoE, Efremov DG, Ghiotto F, AllenSL, Kolitz J, Damle R, Fais F, Messmer D, Rai KR, Ferrarini M, Chiorazzi N. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004 Aug 16;200(4):519-25. 
• Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004 Aug 26;351(9):893-901. 
• Byrd JC, Peterson BL, Gabrilove JL, Odenike OM, Grever MR, Rai KR, Vardiman JW, Larson RA, Cancer and Leukemia Group B. Sequential phase II studies of flavopiridol by 72-hour continuous infusion and 1-hour intravenous bolus for the treatment of relapsed B-cell chronic lymphocytic leukemia: results from CALGB study 19805. Blood. 2004 Nov 16;104(11):3485. 

2005

• Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005 Jan 1;105(1):49-53. Epub 2004 May 11. 
• Chiorazzi N, Rai KR, Ferrarini M. Chronic Lymphocytic Leukemia. N Engl J Med. 2005 Feb 24;352(8):804-15. 
• Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, Murphy EJ, Koduru P, Ferrarini M, Zupo S, Cutrona G, Damle RN, Wasil T, Rai KR, Hellerstein MK, Chiorazzi N. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005 Mar;115(3):755-64. 
• Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005 Nov;29(11):1253-7. 

2006

• Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Döhner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K; International Workshop on Chronic Lymphocytic Leukemia (IWCLL). Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006 Feb 1;107(3):859-61. Epub 2005 Oct 13. 
• Rai KR. Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia. Semin Oncol. 2006 Apr;33(2 Suppl 5):S15-22. 

2007

• O’Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2007 Mar 20;25(9):1114-20. Epub 2007 Feb 12. 
• Rai KR. Pathophysiologic mechanisms of chronic lymphocytic leukemia and their application to therapy. Exp Hematol. 2007 Apr;35(4 Suppl 1):134-6.
• Byrd JC, O’Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55. 
• Rai KR. Introduction: Chronic lymphocytic leukemia in perspective. Best Pract Res Clin Haematol. 2007 Sep;20(3):363-5. 
• Damle RN, Temburni S, Calissano C, Yancopoulos S, Banapour T, Sison C, Allen SL, Rai KR, Chiorazzi N. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood. 2007 Nov 1;110(9):3352-9. Epub 2007 Aug 7. 

2008

• Widhopf GF, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG, Rai KR, Kipps TJ. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood. 2008 Mar 15;111(6):3137-44. Epub 2007 Aug 3. 
• Kaufman M, Rai KR. Alemtuzumab in the up-front setting. Ther Clin Risk Manag. 2008 Apr;4(2):459-64. 
• Rai KR. The natural history of CLL and new prognostic markers. Clin Adv Hematol Oncol. 2008 May;6(5):4-5; quiz 10-2.
• Ghia EM, Jain S, Widhopf GF 2nd, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008 May 15;111(10):5101-8. Epub 2008 Mar 7. 
• Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446-56. Epub 2008 Jan 23. 
• Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008 Sep 1;112(5):1923-30. Epub 2008 Jun 24. 
• McCarthy BA, Boyle E, Wang XP, Guzowski D, Paul S, Catera R, Trott J, Yan XJ, Croce CM, Damle R, Yancopoulos S, Messmer BT, Lesser M, Allen SL, Rai KR, Chiorazzi N. Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18). Mol Med. 2008 Sep-Oct;14(9-10):618-27. 
• Catera R, Silverman GJ, Hatzi K, Seiler T, Didier S, Zhang L, Hervé M, Meffre E, Oscier DG, Vlassara H, Scofield RH, Chen Y, Allen SL, Kolitz J, Rai KR, Chu CC, Chiorazzi N. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med. 2008 Nov-Dec;14(11-12):665-74. Epub 2008 Sep 25. 
• Chu CC, Catera R, Hatzi K, Yan XJ, Zhang L, Wang XB, Fales HM, Allen SL, Kolitz JE, Rai KR, Chiorazzi N. Chronic Lymphocytic Leukemia Antibodies With A Common Stereotypic Rearrangement Recognize Non-Muscle Myosin Heavy Chain IIA. Blood. 2008 Dec 15;112(13):5122-9. Epub 2008 Sep 23. 

2009

• Grubor V, Krasnitz A, Troge JE, Meth JL, Lakshmi B, Kendall JT, Yamrom B, Alex G, Pai D, Navin N, Hufnagel LA, Lee YH, Cook K, Allen SL, Rai KR, Damle RN, Calissano C, Chiorazzi N, Wigler M, Esposito D. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood. 2009 Feb 5;113(6):1294-303. Epub 2008 Oct 15. 
• Kaufman M, Limaye SA, Driscoll N, Johnson C, Caramanica A, Lebowicz Y, Patel D, Kohn N, Rai K. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma. 2009 Jun;50(6):892-9. 
• Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, Larson RA. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma. 2009 Oct;50(10):1589-96. 
• Seiler T, Woelfle M, Yancopoulos S, Catera R, Li W, Hatzi K, Moreno C, Torres M, Paul S, Dohner H, Stilgenbauer S, Kaufman MS, Kolitz JE, Allen SL, Rai KR, Chu CC, Chiorazzi N. Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. Blood. 2009 Oct 22;114(17):3615-24. Epub 2009 Aug 18. 
• O’Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan- Khan AA, Seymour JF, Gribben S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF, Gribben J, Itri LM, Rai KR. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol. 2009 Nov 1;27(31):5208-12. Epub 2009 Sep 8. 
• Kaufman M, Rubin J, Rai K. Diagnosing and treating chronic lymphocytic leukemia in 2009. Oncology (Williston Park). 2009 Nov 15;23(12):1030-7. 
• Calissano C, Damle RN, Hayes G, Murphy EJ, Hellerstein MK, Moreno C, Sison C, Kaufman MS, Kolitz JE, Allen SL, Rai KR, Chiorazzi N. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood. 2009 Nov 26;114(23):4832-42. Epub 2009 Sep 29. 

2010

• Wojcik SE, Rossi S, Shimizu M, Nicoloso MS, Cimmino A, Alder H, Herlea V, Rassenti LZ, Rai KR, Kipps TJ, Keating MJ, Croce CM, Calin GA. Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis. 2010 Feb;31(2):208-15. Epub 2009 Nov 19. 
• Kaufman M, Rai K. The challenge of treating complex autoimmune cytopenias in chronic lymphocytic leukemia. Leuk Lymphoma. 2010 Apr;51(4):574-5. 
• Chu CC, Catera R, Zhang L, Didier S, Agagnina BM, Damle RN, Kaufman MS, Kolitz JE, Allen SL, Rai KR, Chiorazzi N. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood. 2010 May 13;115(19):3907-15. Epub 2010 Jan 28.
• Hayes GM, Busch R, Roogt J, Siah IM, Gee TA, Hellerstein MK, Chiorazzi N, Rai KR, Murphy EJ. Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: validation of a simplified method suitable for multi-center clinical studies. Leuk Res. 2010 Jun;34(6):809-15. Epub 2009 Oct 24. 
• Heerema NA, Byrd JC, Dal Cin PS, Dell’ Aquila ML, Koduru PR, Aviram A, Smoley SA, Rassenti LZ, Greaves AW, Brown JR, Rai KR, Kipps TJ, Kay NE, Van Dyke DL; Chronic Lymphocytic Leukemia Research Consortium. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet. 2010 Dec;203(2):134-40. 
• Smoley SA, Van Dyke DL, Kay NE, Heerema NA, Dell’ Aquila ML, Dal Cin P, Koduru P, Aviram A, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Eckel-Passow J, Neuberg D, Kipps TJ, Dewald GW. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet. 2010 Dec;203(2):141-8. 

2011

• Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell’Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011 Jan 5;305(1):59-67. 
• Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, Teoh N, Horne H, Wegener WA, Goldenberg DM. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin’s lymphoma. Haematologica. 2011 Apr;96(4):567-73. Epub 2010 Dec 20. 
• Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA, Byrd JC. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011 Apr 1;29(10):1349-55. Epub 2011 Feb 14. 
• Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PE, Simone R, Chum P, Yan XJ, Allen SL, Kolitz JE, Baskar S, Rader C, Mellstedt H, Lee A, Gregersen PK, Rai KR, Chiorazzi N. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood. 2011 May 19;117(20):5463-72. Epub 2011 Mar 8. 
• Porakishvili N, Memon A, Vispute K, Kulikova N, Clark EA, Rai KR, Nathwani A, Damle RN, Chiorazzi N, Lydyard PM. CD180 functions in activation, survival and cycling of B chronic lymphocytic leukaemia cells. Br J Haematol. 2011 May;153(4):486-98. Epub 2011 Mar 28. 
• Kaufman MS, Caramanica A, Janson D, Driscoll N, Johnson C, Kohn N, Wasil T, Rai KR. Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia. Med Oncol. 2011 Jun;28(2):532-8. Epub 2010 Mar 17. 
• Rai KR, Hollweg A. Fludarabine versus chlorambucil: is the debate over? Clin Lymphoma Myeloma Leuk. 2011 Jun;11(Suppl 1):S7-9. Epub 2011 May 7. 
• Cheson BD, Rai KR, Friedberg JW. Accurate reporting of adverse events in chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2011 Jul;9(7 Suppl 15):1-11. 
• Chu CC, Zhang L, Dhayalan A, Agagnina BM, Magli AR, Fraher G, Didier S, Johnson LP, Kennedy WJ, Damle RN, Yan X-J, Patten PEM, Teichberg S, Koduru P, Kolitz JE, Allen SL, Rai KR, Chiorazzi N. Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera. Mol Med. 2011;17(11-12):1338-48. Epub 2011 Sep 21. 
• Calissano C, Damle RN, Marsilio S, Yan X-J, Yancopoulos S, Hayes G, Emson C, Murphy EJ, Hellerstein MK, Sison C, Kaufman MS, Kolitz JE, Allen SL, Rai KR, Ivanovic I, Dozmorov IM, Roa S, Scharff MD, Li W, Chiorazzi N. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med. 2011;17(11-12):1374-82. Epub 2011 Sep 23. 
• Yan X-J, Dozmorov I, Li W, Yancopoulos S, Sison C, Centola M, Jain P, Allen SL, Kolitz JE, Rai KR, Chiorazzi N, Sherry B. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood. 2011 Nov 10;118(19):5201-10. Epub 2011 Sep 12. 
• Rai KR, Jain P. Advances in the clinical staging of chronic lymphocytic leukemia. Clin Chem. 2011 Dec;57(12):1771-2. Epub 2011 Aug 11. 

2012

• Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA, Rosenwald A, Allen SL, Kolitz JE, Rai KR, Chiorazzi N, Sherry B. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica. 2012 Apr;97(4):599-607. Epub 2011 Nov 4. 
• Cheson BD, Byrd JC, Rai KR, Kay NE, O’Brien SM, Flinn IW, Wiestner A, Kipps TJ. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012 Aug 10;30(23):2820-2. Epub 2012 Jul 9. 
• Lozanski G, Ruppert AS, Heerema NA, Lozanski A, Lucas DM, Gordon A, Gribben JG, Morrison VA, Rai KM, Marcucci G, Larson RA, Byrd JC. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. Leuk Lymphoma. 2012 Sep;53(9):1743-8. Epub 2012 Jun 2. 
• Damle RN, Temburni S, Banapour T, Paul S, Mongini PKA, Allen SL, Kolitz JE, Rai KR, Chiorazzi N. T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients. Blood. 2012 Sep 20;120(12):2438-49. Epub 2012 Aug 8. 
• Jain P, Rai KR. Overview of recent developments in chronic lymphocytic leukemia. South Asian J Cancer. 2012 Oct;1(2):84-9. 
• Patten PE, Chu CC, Albesiano E, Damle RN, Yan XJ, Kim D, Zhang L, Magli AR, Barrientos J, Kolitz JE, Allen SL, Rai KR, Roa S, Mongini PK, MacCarthy T, Scharff MD, Chiorazzi N. IGHV unmutated and mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. Blood. 2012 Dec 6;120(24):4802-11. Epub 2012 Oct 15. 

2013

• Solh M, Rai KR, Peterson BL, Kolitz JE, Appelbaum FR, Tallman MS, Belch A, Larson RA, Morrison VA. The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma. 2013 Feb;54(2):252-4. Epub 2012 Sep 8. 
• Cesano A, Perbellini O, Evensen E, Chu CC, Cioffi F, Ptacek J, Damle RN, Chignola R, Cordeiro J, Yan XJ, Hawtin RE, Nichele I, Ware JR, Cavallini C, Lovato O, Zanotti R, Rai KR, Chiorazzi N, Pizzolo G, Scupoli MT. Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies. Haematologica. 2013 Apr;98(4):626-34. Epub 2012 Nov 9. 
• Barrientos J, Rai K. Ibrutinib: a novel Bruton’s tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Aug;54(8):1817-20. 
• Liu Y, Higgins CD, Overstreet CM, Rai KR, Chiorazzi N, Lai JR. Peptides that specifically bind to an antibody from a chronic lymphocytic leukemia clone expressing unmutated immunoglobulin variable region genes. Mol Med. 2013 Aug 28;19:245-52. 
• Jones JA, Ruppert AS, Zhao W, Lin TS, Rai K, Peterson B, Larson RA, Marcucci G, Heerema NA, Byrd JC. Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Leuk Lymphoma. 2013 Dec;54(12):2654-9. Epub 2013 May 9. 

2014

• Hwang KK, Trama AM, Kozink DM, Chen X, Wiehe K, Cooper AJ, Xia SM, Wang M, Marshall DJ, Whitesides J, Alam M, Tomaras GD, Allen SL, Rai KR, McKeating J, Catera R, Yan XJ, Chu CC, Kelsoe G, Liao HX, Chiorazzi N, Haynes BF. IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. PLoS One. 2014 Mar 10;9(3):e90725. 
• Rai KR, Barrientos JC. Movement toward optimization of CLL therapy. N Engl J Med. 2014 Mar 20;370(12):1160-2. 
• Houldsworth J, Guttapalli A, Thodima V, Yan XJ, Mendiratta G, Zielonka T, Nanjangud G, Chen W, Patil S, Mato A, Brown JR, Rai K, Chiorazzi N, Chaganti RSK. Genomic imbalance defines three prognostic groups for risk stratification of chronic lymphocytic leukemia patients. Leuk Lymphoma. 2014 Apr;55(4):920-8. Epub 2013 Nov 12. 
• James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol. 2014 Jul 1;32(19):2067-73. Epub 2014 May 27. 
• Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 3;124(1):42-8. Epub 2014 May 27. 

2015

• Porakishvili N, Vispute K, Steele AJ, Rajakaruna N, Kulikova N, Tsertsvadze T, Nathwani A, Damle RN, Clark EA, Rai KR, Chiorazzi N, Lydyard PM. Rewiring of sIgM-mediated intracellular signaling through the CD180 Toll-like receptor. Mol Med. 2015 Apr;21(1):46-57. Epub 2015 Jan 14. 
• Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O’Brien S. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015 May 7;125(19):2915-22. Epub 2015 Mar 9. 
• Tuveson D, Rai KR. Augmenting NF-κB in poor-risk CLL: A general paradigm for other cancers? J Exp Med. 2015 Jun 1;212(6):830-1. 
• Rai KR. Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol. 2015 Jul 14;8:85. 
• Mongini PKA Gupta R, Boyle E, Nieto J, Lee H, Stein J, Bandovic J, Stankovic T, Barrientos J, Kolitz JE, Allen SL, Rai K, Chu CC, Chiorazzi N. TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells. J Immunol. 2015 Aug 1;195(3):901-23. Epub 2015 Jul 1. 
• Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med. 2015 Oct 29;373(18):1733-47. Epub 2015 Sep 9. 
• Sherry B, Jain P, Chiu PY, Leung L, Allen SL, Kolitz JE, Rai KR, Barrientos J, Liang S, Hawtin R, Chiorazzi N. Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes. Immunol Res. 2015 Dec;63(1-3):216-27. 
• McCarthy BA, Yancopoulos S, Tipping M, Yan X-J, Wang XP, Bennett F, Li W, Lesser M, Paul S, Boyle E, Moreno C, Catera R, Messmer BT, Cutrona G, Ferrarini M, Kolitz JE, Allen SL, Rai KR, Rawstron AC, Chiorazzi N. A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes. Immunol Res. 2015 Dec;63(1-3):90-100. 

2016

• Kalaycio ME, George Negrea O, Allen SL, Rai KR, Abbasi RM, Horne H, Wegener WA, Goldenberg DM. Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia. Leuk Lymphoma. 2016;57(4):803-11. Epub 2015 Oct 19. 
• Rai KR, Jain P. Chronic lymphocytic leukemia (CLL)-Then and now. Am J Hematol. 2016 Mar;91(3):330-40. 
• Chen SS, Chang BY, Chang S, Tong T, Ham S, Sherry B, Burger JA, Rai KR, Chiorazzi N. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016 Apr;30(4):833-43. Epub 2015 Nov 9. 
• Patten PE, Ferrer G, Chen SS, Simone R, Marsilio S, Yan XJ, Gitto Z, Yuan C, Kolitz JE, Barrientos J, Allen SL, Rai KR, MacCarthy T, Chu CC, Chiorazzi N. Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process. JCI Insight. 2016 Apr 7;1(4). pii: e86288. 
• Cui X, Zhang L, Magli AR, Catera R, Yan XJ, Griffin DO, Rothstein TL, Barrientos J, Kolitz JE, Allen SL, Rai KR, Chiorazzi N, Chu CC. Cytoplasmic myosin exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability. Leukemia. 2016 Jan;30(1):74-85. Epub 2015 Jul 29. 
• Getta BM, Woo KM, Devlin S, Park JH, Abdel-Wahab O, Saven A, Rai K, Tallman MS. Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. Br J Haematol. 2016 Nov;175(3):402-409. Epub 2016 Jun 28. 
• Hatzi K, Catera R, Moreno Atanasio C, Fischetti VA, Allen SL, Kolitz JE, Rai KR, Chu CC, Chiorazzi N. Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity and IGHV mutation status. Clin Immunol. 2016 Nov;172:44-51. Epub 2016 Aug 29. 
• de Vos S, Wagner-Johnston ND, Coutre SE, Flinn IW, Schreeder MT, Fowler NH, Sharman JP, Boccia RV, Barrientos JC, Rai KR, Boyd TE, Furman RR, Kim Y, Godfrey WR, Leonard JP. Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma. Blood Adv. 2016 Nov 30;1(2):122-131. eCollection 2016 Dec 13. 
• Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016 Dec 22;128(25):2931-2940. Epub 2016 Nov 4. 

2017

• Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O’Brien S, Gribben J, Rai K. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 Jan 19;3:16096. 
• Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017 Feb 2;129(5):553-560. Epub 2016 Nov 30. 
• Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O’Brien S, Gribben J, Rai K. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 Feb 9;3:17008. 
• Catera R, Liu Y, Gao C, Yan XJ, Magli A, Allen SL, Kolitz JE, Rai KR, Chu CC, Feizi T, Stamatopoulos K, Chiorazzi N. Binding of CLL subset 4 B-cell receptor immunoglobulins to viable human memory B lymphocytes requires a distinctive IGKV somatic mutation. Mol Med. 2017 Mar;23:1-12. Epub 2017 Jan 12. 
• Murphy EJ, Neuberg DS, Rassenti LZ, Hayes G, Redd R, Emson C, Li K, Brown JR, Wierda WG, Turner S, Greaves AW, Zent CS, Byrd JC, McConnel C, Barrientos J, Kay N, Hellerstein MK, Chiorazzi N, Kipps TJ, Rai KR. Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. Leukemia. 2017 Jun;31(6):1348-1354. Epub 2017 Jan 24. 
• Bosch R, Ferrer G, Damle R, Jansà S, Gorlatov S, Nomdedéu J, Martino R, Novelli S, Garrido A, Garcia I, Granell M, Rai K, Montserrat E, Sierra J, Chiorazzi N, Moreno C. FcγRIIb expression in early stage chronic lymphocytic leukemia. Leuk Lymphoma. 2017 Nov;58(11):2642-2648. Epub 2017 Apr 4. 

2018

• Sammartino D, Khanijo S, Koenig S, Katsetos JF, Tufano A, Rai KR, Barrientos JC. Chylothorax in Patients with Chronic Lymphocytic Leukemia: A Case Series. J Hematol (Brossard). 2018 Jan;7(1):14-18. 
• Marsilio S, Khiabanian H, Fabbri G, Vergani S, Scuoppo C, Montserrat E, Shpall EJ, Hadigol M, Marin P, Rai KR, Rabadan R, Devereux S, Pasqualucci L, Chiorazzi N. Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity. Leukemia. 2018 Apr;32(4):1041-1044. Epub 2017 Dec 5. 
• Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O’Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. Epub 2018 Mar 14. 
• Gupta R, Yan XJ, Barrientos J, Kolitz JE, Allen SL, Rai K, Chiorazzi N, Mongini PKA. Mechanistic insights into CpG DNA and IL-15 synergy in promoting B cell chronic lymphocytic leukemia clonal expansion. J Immunol. 2018 Sep 1;201(5):1570-1585. Epub 2018 Aug 1. 

2019

• Sharma S, Rai KR. Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options. Cancer. 2019 May 1;125(9):1432-1440. Epub 2019 Feb 26. 
• Gupta R, Li W, Yan XJ, Barrientos J, Kolitz JE, Allen SL, Rai K, Chiorazzi N, Mongini PK. Mechanism for IL-15–Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins. J Immunol. 2019 May 15;202(10):2924-2944. Epub 2019 Apr 15. 
• Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019 Jun;570(7762):474-479. Epub 2019 May 29. 
• Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood. 2019 Aug 22;134(8):688-698. Epub 2019 Jul 10. 

2020

• Bartholdy BA, Wang X, Yan XJ, Pascual M, Fan M, Barrientos J, Allen SL, Martinez-Climent JA, Rai KR, Chiorazzi N, Scharff MD, Roa S. CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation. Blood Adv. 2020 Mar 10;4(5):893-905. 
• Bosch R, Mora A, Cuellar C, Ferrer G, Gorlatov S, Nomdedéu J, Montserrat E, Sierra J, Rai KR, Chiorazzi N, Moreno C. FcγRIIb-BCR Co-Ligation Inhibits BCR Signaling in Chronic Lymphocytic Leukemia. Haematologica. 2020 Mar 26. [Epub ahead of print] 
• Chiorazzi N, Chen SS, Rai KR. Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med. 2020 Mar 30. [Epub ahead of print] 

2021

Ferrer G, Jung B, Chiu PY, Aslam R, Palacios F, Mazzarello AN, Vergani S, Bagnara D, Chen SS, Yancopoulos S, Xochelli A, Yan XJ, Burger JA, Barrientos JC, Kolitz JE, Allen SL, Stamatopoulos K, Rai KR, Sherry B, Chiorazzi N. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. Leukemia. 2021 May 2. [Epub ahead of print].